摘要
目的贯彻落实河北省卫生健康委《河北省公立医疗机构用药目录遴选评价管理指南》的要求,为医院决策者遴选、临床合理使用磺脲类降糖药物提供循证依据。方法依照指南制定的百分制评分体系,参考药品说明书、临床指南和文献,从安全性、有效性、经济性、创新性、适宜性和可及性等6个方面分别对格列喹酮片、格列齐特缓释片和格列美脲片进行医院卫生技术评估。结果格列喹酮片、格列齐特缓释片和格列美脲片最终分值分别为72.5、71和73分;3者用于治疗2型糖尿病均可有效降低患者的餐后血糖;患者可结合自身条件及需求合理选择使用药品;与其他药物合用时应注意药物相互作用的影响,需密切监测血糖,防止低血糖的发生。结论本次卫生技术评估可为医疗机构开展药品评价与遴选提供指导,同时为临床合理使用磺脲类降糖药提供循证依据。
OBJECTIVE To implement the requirements of Hebei Provincial Health Commission"Guidelines for the Selection,Evaluation and Management of Drug Catalogue in Public Medical Institutions in Hebei Province",and provide evidence-based basis for decision makers to select and rationally use sulfonylureas drugs in hospitals.METHODS According to the 100-point scoring system specified in the guidelines and referring to the drug instructions,clinical guidelines and literature,the hospital health technology was evaluated from six aspects,including safety,efficacy,economy,innovation,suitability and accessibility.RESULTS The final scores of gliquidone,gliclazide and glimepiride were 72.5,71 and 73,respectively.All of them can effectively reduce postprandial blood glucose in patients with type 2 diabetes,with good safety.In addition,a variety of enzyme inducers or inhibitors can interact with SUs,so attention should be paid to the influence of drug interactions during the application of patients.Patients with type 2 diabetes can choose drugs according to their own conditions and needs.When combined with other drugs,blood glucose should be closely monitored to prevent the occurrence of hypoglycemia.CONCLUSION This health technology assessment can provide guidance for medical institutions in drug evaluation and selection,and provide evidence-based basis for clinical rational use of sulfonylureas hypoglycemic drugs.
作者
邱博
李宵
杨浩天
杜润璇
董占军
QIU Bo;LI Xiao;YANG Hao-tian;DU Run-xuan;DONG Zhan-jun(Hebei General Hospital,Shijiazhuang 050051,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2021年第2期153-161,共9页
Chinese Pharmaceutical Journal
